What Is Genomics?
Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.
Your trusted source for investing success
Your trusted source for investing success
Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Intellia Therapeutics released its financial results for the second quarter of 2017.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of each.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.
By Pia Rivera
HTG Molecular Diagnostics leads the list of last week’s life science gainers on the NASDAQ, followed by La Jolla Pharmaceutical, Dynavax Technologies, NewLink Genetics and BioCryst Pharmaceutical.
ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.
Results from the study entitled “In vivo genome editing with a small Cas9 orthologue derived
By Pia Rivera
Thom Calandra is known to investors in the resource space. Recently, he wrote about biotechnology and started his own index of companies he follows, called Genes, Genes on Motif.
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced updated data from the ongoing gene therapy clinical trial for Sanfilippo syndrome Type A (MPS IIIA), at the 13th Annual WORLDSymposium™ 2017 lysosomal storage disorders conference in San Diego, CA. The
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
